4.6 Article

Impact of Postoperative C-Reactive Protein Level on Recurrence and Prognosis in Patients With N0M0 Clear Cell Renal Cell Carcinoma

Journal

JOURNAL OF UROLOGY
Volume 186, Issue 2, Pages 430-435

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1016/j.juro.2011.03.113

Keywords

kidney; carcinoma, renal cell; C-reactive protein; neoplasm metastasis; mortality

Ask authors/readers for more resources

Purpose: Preoperative C-reactive protein is a strong predictor of recurrence and prognosis in patients with renal cell carcinoma while postoperative C-reactive protein reportedly predicts survival in patients with metastatic renal cell carcinoma. We evaluated the impact of postoperative C-reactive protein on recurrence and prognosis in patients with N0M0 clear cell renal cell carcinoma. Materials and Methods: We defined increased preoperative C-reactive protein as 1 mg/dl or greater and postoperative C-reactive protein normalization as at least 1 postoperative measurement of less than 0.3 mg/dl. We reviewed the records of 263 patients with N0M0 clear cell renal cell carcinoma who underwent nephrectomy, and in whom preoperative and postoperative C-reactive protein values were available. We used multivariate analysis to identify independent factors predicting recurrence and prognosis. We also evaluated C-reactive protein at recurrence and its impact on survival. Results: Increased preoperative C-reactive protein and nonnormalization of postoperative C-reactive protein were associated with worse clinicopathological factors. Postoperative C-reactive protein nonnormalization, increased preoperative C-reactive protein, microvascular invasion and histological tumor necrosis were independent predictors for recurrence. Risk stratification using these factors effectively predicted the possibility of recurrence. Anemia, thrombocytosis and postoperative C-reactive protein nonnormalization were independent predictors of overall survival. Postoperative followup revealed recurrence in 50 patients. The 3-year survival rate in patients with C-reactive protein 0.3 mg/dl or greater at recurrence was significantly lower than that in patients with less than 0.3 mg/dl at recurrence (47.3% vs 81.6%). Conclusions: Nonnormalization of postoperative C-reactive protein is a strong predictor of recurrence and prognosis. Patients with C-reactive protein 0.3 mg/dl or greater at recurrence might not survive as long as those with C-reactive protein less than 0.3 mg/dl at recurrence.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Fluvastatin potentiates anticancer activity of vorinostat in renal cancer cells

Kazuki Okubo, Makoto Isono, Kosuke Miyai, Takako Asano, Akinori Sato

CANCER SCIENCE (2020)

Article Multidisciplinary Sciences

Inhibition of checkpoint kinase 1 potentiates anticancer activity of gemcitabine in bladder cancer cells

Makoto Isono, Kazuki Okubo, Takako Asano, Akinori Sato

Summary: Combining MK-8776 with gemcitabine inhibits viability and colony formation of bladder cancer cells, induces apoptosis, and suppresses tumor growth in vivo. The combination treatment elevates gamma H2A.X and suppresses Rad51 expression, suggesting CHK1 inhibition combined with gemcitabine as a potential therapeutic strategy for bladder cancer.

SCIENTIFIC REPORTS (2021)

Article Oncology

Ubiquitin-proteasome System Is a Promising Target for Killing Cisplatin-resistant Bladder Cancer Cells

Kazuki Okubo, Makoto Isono, Takako Asano, Nina Ressing, Wolfgang A. Schulz, Finn K. Hansen, Akinori Sato

Summary: The study found that UPS was activated in cisplatin-resistant bladder cancer cells, and UPS-targeting drugs were more effective in inducing apoptosis and inhibiting growth in cisplatin-resistant cells. Furthermore, these drugs could induce endoplasmic reticulum stress at lower concentrations in cisplatin-resistant bladder cancer cells.

ANTICANCER RESEARCH (2021)

Article Oncology

Simvastatin-romidepsin combination kills bladder cancer cells synergistically

Kazuki Okubo, Kosuke Miyai, Kimi Kato, Takako Asano, Akinori Sato

Summary: The combination of simvastatin and romidepsin induces histone acetylation cooperatively, leading to apoptosis of bladder cancer cells. The activation of AMPK by the combination also results in ER stress, promoting reactive oxygen species production. Additionally, there is a positive feedback loop between ER stress induction and PPAR gamma expression in the combination therapy.

TRANSLATIONAL ONCOLOGY (2021)

Article Oncology

The Dual Histone Deacetylase-Proteasome Inhibitor RTS-V5 Acts Synergistically With Ritonavir to Induce Endoplasmic Reticulum Stress in Bladder Cancer Cells

Kazuki Okubo, Nina Ressing, Wolfgang A. Schulz, Finn K. Hansen, Takako Asano, Akinori Sato

Summary: Ritonavir enhances the ability of RTS-V5 to induce ER stress in bladder cancer cells by increasing the expression of AMP-activated protein kinase and causing histone and tubulin hyperacetylation.

ANTICANCER RESEARCH (2021)

Meeting Abstract Oncology

Cobicistat acts synergistically with oprozomib to cause endoplasmic reticulum stress in renal cancer cells

Takako Asano, Kazuki Okubo, Akinori Sato

CANCER SCIENCE (2022)

Meeting Abstract Oncology

The ataxia telangiectasia and Rad3-related kinase inhibitor AZD6738 overcomes cisplatin resistance in bladder cancer

Makoto Isono, Akinori Sato, Kazuki Okubo, Takako Asano, Toshihiko Torigoe

CANCER SCIENCE (2021)

Meeting Abstract Oncology

Ritonavir and oprozomib inhibit renal cancer growth by inducing endoplasmic reticulum stress

Takako Asano, Kazuki Okubo, Akinori Sato

CANCER SCIENCE (2021)

Article Urology & Nephrology

Prostate cancer recurrence mimicking invasive urothelial cancer of the bladder

Kazuki Okubo, Fumiko Hamabe, Kosuke Miyai, Makoto Isono, Hiroshi Shinmoto, Akinori Sato

UROLOGY CASE REPORTS (2020)

Meeting Abstract Urology & Nephrology

RITONAVIR AND OPROZOMIB INHIBIT RENAL CANCER GROWTH BY INDUCING ENDOPLASMIC RETICULUM STRESS

Takako Asano, Kazuki Okubo, Akinori Sato

JOURNAL OF UROLOGY (2020)

Meeting Abstract Urology & Nephrology

PANOBINOSTAT AND RITONAVIR CAUSE BLADDER CANCER APOPTOSIS BY INDUCING ENDOPLASMIC RETICULUM STRESS AND HISTONE ACETYLATION SYNERGISTICALLY

Akinori Sato, Takako Asano, Makoto Isono, Kazuki Okubo

JOURNAL OF UROLOGY (2019)

Meeting Abstract Urology & Nephrology

COBICISTAT, A POTENT CYP3A4 INHIBITOR, ACTS SYNERGISTICALLY WITH OPROZOMIB TO CAUSE ENDOPLASMIC RETICULUM STRESS IN BLADDER CANCER CELLS

Akinori Sato, Takako Asano, Makoto Isono, Kazuki Okubo

JOURNAL OF UROLOGY (2019)

Meeting Abstract Urology & Nephrology

FLUVASTATIN POTENTIATES ANTICANCER ACTIVITY OF VORINOSTAT IN RENAL CANCER CELLS BY ACTIVATING AMP-ACTIVATED PROTEIN KINASE

Kazuki Okubo, Makoto Isono, Takako Asano, Akinori Sato

JOURNAL OF UROLOGY (2019)

No Data Available